Skip to main content
. Author manuscript; available in PMC: 2016 Jan 14.
Published in final edited form as: Nucl Med Biol. 2011 Sep 29;39(2):215–226. doi: 10.1016/j.nucmedbio.2011.07.007

Fig. 4.

Fig. 4

Uptake of [18F]-DA (A and B) and [18F]-DOPA (C and D) in MPC cells presented as “normalized ratio of controls” at 10 and 120 min after treatment with 1 μM desipramine (DMI), 10 μM reserpine (RES), 10 μM tetrabenazine (TET) and their combination (30 min before adding the [18F]-DA and [18F]-DOPA). *P<.05, **P<.001 ***P<.0001 versus control (“C”). +P<.05, ++P<.001 versus desipramine (“DMI”).